Sanofi SA Unsponsored CDR Hedged Reg S (SNY) Stock Price & Analysis

3 Followers

SNY Stock Chart & Stats

CA$22.36-CA$0.04(-0.18%)

At close: Nov 12 4:00 PM EST

Day’s Range: CAD 22.36 - CAD 22.36
52-Week Range: CAD 18.13 - CAD 23.03
Previous Close: CAD 22.40
Volume: N/A
Average Volume (3M): 1,659
Market Cap: CAD 163.02B
Enterprise Value: N/A
Total Cash (Recent Filing): N/A
Total Debt (Recent Filing): N/A
Price to Earnings (P/E): 24.8
Beta: 0.39
Next Earnings: Jan 28, 2027 (Est.)
EPS Estimate: N/A
Last Dividend Ex-Date: May 06, 2026
Dividend Yield: 3.71%

Sanofi SA Unsponsored CDR Hedged Reg S News

Sanofi upgraded to Outperform from Neutral at BNP Paribas

BNP Paribas analyst Peter Verdult upgraded Sanofi (SNY) to Outperform from Neutral with a EUR 102 price target The firm believes the near-term earnings growth of Dupixent is being overlook

3d agoSNY SNW

Midday Fly By: Democrats win major victories, AMD reports upbeat Q3

The major averages were sharply higher following Tuesday’s midterm elections, as Democrats retook the Senate and House of Representatives and won multiple state governorships. The conclusion of the midterm elections,

1w agoEW KD

Sanofi price target raised to EUR 86 from EUR 82 at Morgan Stanley

Morgan Stanley analyst Thibault Boutherin raised the firm’s price target on Sanofi (SNY) to EUR 86 from EUR 82 and keeps an Equal Weight rating on the shares. Published first

1w agoSNY SNW

Sanofi price target raised to EUR 90 from EUR 83 at Barclays

Barclays raised the firm’s price target on Sanofi (SNY) to EUR 90 from EUR 83 and keeps an Equal Weight rating on the shares. Published first on TheFly – the

1w agoSNY SNW

Sanofi price target raised to EUR 80 from EUR 75 at RBC Capital

RBC Capital raised the firm’s price target on Sanofi (SNY) to EUR 80 from EUR 75 and keeps a Sector Perform rating on the shares. The company reported a significant

1w agoSNY SNW

Morning Movers: Intel continues to plummet after earnings

Stock futures are sharply lower as disappointing outlooks from Amazon and Intel extend a technology-sector selloff. Amazon’s holiday-quarter sales outlook disappointed, while Intel also issued a weaker-than-expected Q4 forecast. Alphabet

1w agoGD AZN

Alnylam price target lowered to $320 from $350 at Oppenheimer

Oppenheimer lowered the firm’s price target on Alnylam (ALNY) to $320 from $350 and keeps an Outperform rating on the shares. The firm notes Alnylam was under pressure mainly due

1w agoSNY ALNY

Sanofi reports Q3 business EPS EUR 3.55, up 22% reported

Business EPS was EUR 3.55, up by 19.6% at CER; 22.0% at actual exchange rates; IFRS EPS EUR 2.52. Reports net sales EUR 14.4B, up 16.2% reported and 14.3% at

1w agoSNY SNW

Sanofi expects FY26 sales to grow by low-teens percentage at CER

2026 guidance is upgraded: sales are expected to grow by a low-teens percentage at CER. Business EPS at CER is expected to grow by a mid-teens percentage. Published first on

1w agoSNY SNW

Novavax earns $125M milestone as Sanofi launches Phase 3 vaccine trial

Novavax (NVAX) has earned a $125M milestone payment with the initiation of Sanofi’s (SNY) Phase 3 influenza-COVID-19 combination vaccine trial utilizing Novavax’s COVID-19 vaccine, Nuvaxovid. Sanofi’s Phase 3 trial, being

2w agoSNY NVAX

Sanofi: Balanced Risk-Reward as Pipeline Setbacks and Dupixent LOE Temper Growth Outlook, With BD/M&A Execution Key to Equity Story

TD Cowen analyst Steve Scala maintained a Hold rating on Sanofi today and set a price target of $57.00. Steve Scala has given his Hold rating due to a combination

2M agoSNY SNW

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

Austin, Texas, United States, June 23rd, 2026, FinanceWire This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ:QNTM) (CSE:QNTM), was featured in a

4M agoSNY BIIB

Balanced Risk-Reward Amid Promising Lunsekimig Data and Valuation Uncertainty Supports Hold Rating

Analyst Steve Scala of TD Cowen maintained a Hold rating on Sanofi, retaining the price target of $57.00. Steve Scala has given his Hold rating due to a combination of

7M agoSNY SNW

Sanofi: De‑Risked Earnings and Robust Medium‑Term Growth Overlooked by Discounted Valuation

Analyst Sachin Jain of Bank of America Securities maintained a Buy rating on Sanofi, retaining the price target of €102.00. Sachin Jain has given his Buy rating due to a

9M agoSNY SNW

SNY FAQ

What was Sanofi SA Unsponsored CDR Hedged Reg S’s price range in the past 12 months?

Sanofi SA Unsponsored CDR Hedged Reg S lowest stock price was C$18.13 and its highest was C$23.03 in the past 12 months.

What is Sanofi SA Unsponsored CDR Hedged Reg S’s market cap?

Sanofi SA Unsponsored CDR Hedged Reg S’s market cap is C$163.02B.

When is Sanofi SA Unsponsored CDR Hedged Reg S’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Sanofi SA Unsponsored CDR Hedged Reg S overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Sanofi SA Unsponsored CDR Hedged Reg S pay dividends?

Sanofi SA Unsponsored CDR Hedged Reg S pays a dividend of C$0.802 which represents an annual dividend yield of 3.71%. See more information on Sanofi SA Unsponsored CDR Hedged Reg S dividends here

What is Sanofi SA Unsponsored CDR Hedged Reg S’s EPS estimate?

Sanofi SA Unsponsored CDR Hedged Reg S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Sanofi SA Unsponsored CDR Hedged Reg S have?

Sanofi SA Unsponsored CDR Hedged Reg S has 1,207,773,400 shares outstanding.

Which hedge fund is a major shareholder of Sanofi SA Unsponsored CDR Hedged Reg S?

Currently, no hedge funds are holding shares in TSE:SNY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Sanofi SA Unsponsored CDR Hedged Reg S

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi SA Unsponsored CDR Hedged Reg S (SNY) Earnings & Revenues

Historic Earnings Reports

SNY Earnings Call

Q3 2026

Earnings Call SentimentPositive

The call was strongly positive overall. Sanofi reported robust Q3 sales and earnings growth, upgraded 2026 guidance, delivered strong Dupixent, rare disease, and launch performance, expanded its Regeneron alliance, and outlined substantial R&D, AI, China, and business development initiatives. The main challenges were the upcoming Dupixent loss of exclusivity, expected moderation in Dupixent growth, vaccine and supply-related pressures, a pipeline that lags peers, discontinued development programs, and uncertainty around 340B litigation and future royalties. The highlights significantly outweighed the lowlights.

View all TSE:SNY earnings summaries

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	15	1	5
Technical Analysis	3	1	5
Moving Averages	12	0	0

Technical Analysis >

Similar Stocks

Stocks similar to TSE:SNY
Company	Price & Change	Follow
TSE:NOVONovo Nordisk A/S Shs Unsponsored Canadian Depository Receipt Hedged
TSE:PFEPfizer Inc. Shs -CAD hedged- Canadian Depositary Receipt Repr Shs Reg S
TSE:CVSCVS Health Corporation Shs Sponsored Canadian Depositary Receipt Repr Sh
TSE:GILDGilead Sciences, Inc. Shs Unsponsored Canadian Depository Receipt Hedged Reg S
TSE:AMGNAmgen Inc. Shs Sponsored Canadian Depository Receipt Hedged Reg S

Compare TSE:SNY Stocks >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

SNY Stock Chart & Stats

Sanofi SA Unsponsored CDR Hedged Reg S News

Sanofi upgraded to Outperform from Neutral at BNP Paribas

Midday Fly By: Democrats win major victories, AMD reports upbeat Q3

Sanofi price target raised to EUR 86 from EUR 82 at Morgan Stanley

Sanofi price target raised to EUR 90 from EUR 83 at Barclays

Sanofi price target raised to EUR 80 from EUR 75 at RBC Capital

Morning Movers: Intel continues to plummet after earnings

Alnylam price target lowered to $320 from $350 at Oppenheimer

Sanofi reports Q3 business EPS EUR 3.55, up 22% reported

Sanofi expects FY26 sales to grow by low-teens percentage at CER

Novavax earns $125M milestone as Sanofi launches Phase 3 vaccine trial

Sanofi: Balanced Risk-Reward as Pipeline Setbacks and Dupixent LOE Temper Growth Outlook, With BD/M&A Execution Key to Equity Story

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 Trials

Balanced Risk-Reward Amid Promising Lunsekimig Data and Valuation Uncertainty Supports Hold Rating

Sanofi: De‑Risked Earnings and Robust Medium‑Term Growth Overlooked by Discounted Valuation

SNY FAQ

Company Description

Sanofi SA Unsponsored CDR Hedged Reg S

Sanofi SA Unsponsored CDR Hedged Reg S (SNY) Earnings & Revenues

SNY Earnings Call

Earnings Call Sentiment|Positive

Technical Analysis

Overall Consensus

Similar Stocks

Popular Stocks

Become an Expert with TipRanks Premium

Earnings Call SentimentPositive